May 19, 2017
The Israeli life sciences industry has slowed slightly in the past two years, in comparison with the global industry. The window of opportunity for Nasdaq issues closed in 2015-2016, but the venture capital funds continued raising money for financing the next generation of promising companies.
The total number of companies in the industry grew, mainly as a result of a boom in digital health. What has slowed over the past two years is the medical devices sector, the former hot spot, which up until now has been responsible for the most impressive exits in the life sciences industry. The changes in the industry have had a negative impact on this sector, but it is still the largest in the industry, although also the most crowded.
These trends can be seen in a detailed report by Israel Advanced Technology Industries (IATI), managed by CEO Karin Mayer Rubinstein. IATI co-chair and life sciences representative and Pluristem Therapeutics president and CEO Yaky Yanay said today, “We issued our previous report two years ago, so we felt it was about time to issue another report. In the coming months, IATI is due to add to the report and use it in working with institutional investors in Israel and with the government for the purpose of further improving the industry.”
Read More: http://www.globes.co.il/en/article-israeli-life-sciences-cos-up-50-in-a-decade-1001189081